Breast cancer and immunology: Biomarker and therapeutic developments

Cesar Santa-Maria, Sue Jung Park, Sarika Jain, William J. Gradishar

Research output: Contribution to journalReview article

Abstract

While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.

Original languageEnglish (US)
Pages (from-to)1215-1222
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume15
Issue number10
DOIs
StatePublished - Oct 3 2015
Externally publishedYes

Fingerprint

Tumor Biomarkers
Allergy and Immunology
Breast Neoplasms
Immunotherapy
Biomarkers
Antigen Presentation
Proxy
Therapeutics
Neoplasms
Learning
Research
Pharmaceutical Preparations

Keywords

  • biomarkers
  • breast cancer
  • checkpoint inhibitors
  • drug development
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Breast cancer and immunology : Biomarker and therapeutic developments. / Santa-Maria, Cesar; Park, Sue Jung; Jain, Sarika; Gradishar, William J.

In: Expert Review of Anticancer Therapy, Vol. 15, No. 10, 03.10.2015, p. 1215-1222.

Research output: Contribution to journalReview article

Santa-Maria, Cesar ; Park, Sue Jung ; Jain, Sarika ; Gradishar, William J. / Breast cancer and immunology : Biomarker and therapeutic developments. In: Expert Review of Anticancer Therapy. 2015 ; Vol. 15, No. 10. pp. 1215-1222.
@article{727ed4d2328b4a7881f51c271a993e90,
title = "Breast cancer and immunology: Biomarker and therapeutic developments",
abstract = "While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.",
keywords = "biomarkers, breast cancer, checkpoint inhibitors, drug development, immunotherapy",
author = "Cesar Santa-Maria and Park, {Sue Jung} and Sarika Jain and Gradishar, {William J.}",
year = "2015",
month = "10",
day = "3",
doi = "10.1586/14737140.2015.1086270",
language = "English (US)",
volume = "15",
pages = "1215--1222",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Breast cancer and immunology

T2 - Biomarker and therapeutic developments

AU - Santa-Maria, Cesar

AU - Park, Sue Jung

AU - Jain, Sarika

AU - Gradishar, William J.

PY - 2015/10/3

Y1 - 2015/10/3

N2 - While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.

AB - While breast cancer has not historically been considered an immunogenic cancer, recent data demonstrating the powerful anti-cancer effects of immune checkpoints in many cancers, including breast cancer, has reinvigorated the field. Although the responses are generally low with single agents, some patients experience disease control for a long period of time. Selecting appropriate patients for immunotherapy is an important area of research, and many biomarkers are under investigation. Although immunotherapies are still in their early stages of development, learning how to use them in combination with other agents that can alter antigen presentation or other immune elements will be crucial. This review aims to summarize efforts in immune-related biomarker and drug development, particularly as it pertains to breast cancer.

KW - biomarkers

KW - breast cancer

KW - checkpoint inhibitors

KW - drug development

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84942552802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942552802&partnerID=8YFLogxK

U2 - 10.1586/14737140.2015.1086270

DO - 10.1586/14737140.2015.1086270

M3 - Review article

C2 - 26358181

AN - SCOPUS:84942552802

VL - 15

SP - 1215

EP - 1222

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 10

ER -